What is MapLight Therapeutics, Inc. 's cash ratio?

MapLight Therapeutics, Inc. (MPLT) reported cash ratio of 3.9× in Q1 2026.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

MapLight Therapeutics, Inc. MPLT Cash ratio

Cash ratio at other companies

Bristol-Myers SquibbBMY

0.5×0.0×

Johnson & JohnsonJNJ

0.4×-0.3×

Neurocrine BiosciencesNBIX

0.3×-0.1×

Acadia PharmaceuticalsACAD

0.9×+0.2×

AbbVieABBV

0.2×+0.1×

LBR

LB Pharmaceuticals Inc Common StockLBRX

29.4×—

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

cash and equivalents/total current liabilities=3.9×

Based on the most recent quarter.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's cash ratio?: MapLight Therapeutics, Inc. (MPLT) reported cash ratio of 3.9× in Q1 2026.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.